Rallybio says Candid terminates merger agreement, owes $50 million fee

Rallybio Corporation

Rallybio Corporation

RLYB

0.00
  • Candid Therapeutics terminated its merger agreement with Rallybio on May 3, 2026, alongside signing a permitted alternative deal with UCB.
  • Termination triggers a USD 50 million parent termination fee payable to Rallybio.
  • Parties signed a waiver on May 1, 2026, allowing fee payment and certain expense reimbursement on first business day following termination.
  • Rallybio plans to withdraw its Form S-4 registration statement filed March 17, 2026, amended April 24, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-202601), on May 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.